102 results about "Reserpine" patented technology

The present invention relates to methods and compositions for treating or ameliorating the effects of diabetes. In addition, the present invention relates to methods and compositions for treating or preventing hyperglycemia, as well as modulating monoamine levels, islet β-cell insulin secretion, insulin and/or glucagon levels in a patient. In certain preferred embodiments, such methods include administering to a patient an effective amount of a vesicular monoamine transporter type 2 (VMAT2) antagonist, such as tetrabenazine (TBZ), dihydrotetrabenazine (DTBZ), tetrahydroberberine (THB), reserpine, emetine, Compound 6, or enantiomers, optical isomers, diastereomers, N-oxides, crystalline forms, hydrates, metabolites or pharmaceutically acceptable salts thereof.

The invention discloses a drug combination and a preparation method thereof. The compositions of the drug combination comprise reserpine, hydrochlorothiazide, promethazine hydrochloride, dihydralazine sulfate, vitamin B6, calcium pantothenate, vitamin B1, magnesium trisilicate, potassium chloride and one or more acidic substances. The drug combination and the preparation method thereof provided by the invention have the advantages that the manufactured drug combination can be used for treating early-stage and middle-stage hypertension diseases.

A pharmaceutical composition for treating hypertension and a preparation method of the pharmaceutical composition are disclosed. The invention provides compound reserpine tablets, which comprise reserpine, hydrochlorothiazide, vitamin B6, vitamin B1, calcium pantothenate, magnesium trisilicate, potassium chloride, dihydralazine sulfate, promethazine hydrochloride and a pharmaceutically-acceptable carrier, wherein vitamin B1 is available in the form of coated granules.

The invention relates to application of a 20(S)-ginsenoside Rh2, namely 3-O-beta-D-glycopyranoside-dammarane-24-alkenyl-3beta, 12beta, 20(S)-triol compound in the field of pharmacy. The compound can effectively confront reserpine related ptosis or akinesia, L-5-HT related mouse tremble, mouse suspension tail or forced swimming acquired desperation and depression and enhance levodopa behavioral effects under test dose, and has no excitation or inhibition function on central pivot. The safety research shows that the compound has high safety, does not influence the central nervous system, cardiovascular system and respiratory system, and has no mutagenesis function. The compound has high safety and good antidepressant function under the test dose, and the action mechanism of the compound can block the reuptake of NA and DA transmitter so as to increase the concentration correlation of two transmitters of synapse and clearance; and the compound can be used for treating depression.

The invention discloses an absolute quantitative analysis method of lysophosphatidyl choline based on an HPLC-MS/MS detection platform. The absolute quantitative analysis method establishes the HPLC-MS/MS detection platform, takes reserpine as an internal standard to draw the standard curves of LPC 14:0-LPC 18:0 serial substances, verifies the linearity, precision and accuracy of the detection platform, and detects the matrix effect of blood serum. Proven by verification, the HPLC-MS/MS detection platform established by the invention has higher stability and accuracy in detection of the LPC substances in the human blood serum, meets the clinical requirements and is suitable for clinical popularization.

The invention discloses a drug for treating depression. The drug is prepared by evenly mixing 0.3-99.7 parts by weight of industrial hemp seed extract and 99.7-0.3 parts by weight of industrial cannabinoid. It is proved through experiments that the drug can significantly shorten the tail suspension immobilization time of mice of a behavioral despair depression model and significantly shorten immobility time of forced swimming, has an obvious anti-depressant effect on a mouse depression model caused by reserpine and can significantly increase the frequency of spontaneous activities of the mice, and the effects are all superior to those of cannabidiol. The drug can be used for preparing drugs for treating various depression symptoms including endogenous depression, reactive depression, masked depression, secondary depression caused by drugs, climacteric or postnatal depression, depression caused by cerebral trauma or cerebral apoplexy, diabetes combined depression and depressive neurosis and used for preparing drugs for treating symptoms such as secondary learning memory decline and anhedonia caused by depression.

The invention discloses a Chinese medicinal composition for treating depression. The medicine adopts lilies, semen ziziphi apinosae, curcuma longa, hypericum perforatum L., perilla, ginseng, and radix bupleuri as raw materials, which are then separate and extracted by 0-75% ethanol so as to be prepared into certain preparation form. The above six drugs used together can soothe liver and relieve depression, reconcile and activate qi, tranquilize the mind and calm the nerves, and can be used for mild and moderate depression and patients belonging to stagnation of qi due to depression of liver, as well as heart-spleen deficiency. Pharmacodynamic research indicates that: the medicinal composition has substantial antagonistic effects on reserpine induced depression models, mouse akinesia and hypothermia, and can increase the spontaneous movements of tail suspension and forced swimming induced despair animal models, as well as the immobility time of tail suspension and swimming. Clinical research results show that a HAMD (Hamilton depression scale) used for evaluating depression severity and Chinese medicinal syndromes before and after treatment are taken as main curative effect indexes, which show that the Chinese medicinal composition in the invention has substantial curative effects. The composition provided in the invention can be prepared into medically acceptable oral preparations, such as tablets, capsules (soft capsules and hard capsules), granules, and other preparation forms. Clinical effects and pharmacodynamic research prove that the Chinese medicinal composition of the invention has the functions of liver soothing and depression relieving, mind tranquilizing as well as nerve calming, and is an effective medicine special for depression treatment.

A method for treatment of the symptoms of neurologic dysfunctions, including major depression, an autism spectrum disorder (ASD), and schizophrenia. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A.

The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered topically or transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day. In homeopathic use, the reserpine may be administered in the form of a homeopathic dilution, preferably as a 12 C homeopathic dilution of reserpine.

The invention discloses a pharmaceutical composition for the treatment of depression prepared by raw materials of paeoniflorin and albiflorin. The invention also discloses a preparation method of the pharmaceutical composition. The experiments prove that the pharmaceutical composition of the invention can obviously reduce the suspension tail immovability time of the mouse to be tested, from which the antidepressant function of the composition in the experiment can be inferred; the pharmaceutical composition of the invention can obviously withstand the temperature reduction of the mouse caused by the reserpine, from which the relevance of the antidepressan mechanism of the composition and the regulation of the monoamine transmitters can be inferred; and the pharmaceutical composition of the invention can significantly reduce the amounts of horizontal movement and vertical movement of the model rat, reduce the electric shock times in the training period and testing period of step down passive avoidance test, significantly reduce the CRH secretion of hypothalamus and ACTH secretion of hypophysis, and significantly reduce the CORT content in the blood, from which the antidepressant function of the pharmaceutical composition and one of the mechanisms of excessive hyperfunction suppression of HPA axis can be inferred.

The invention discloses an extracting method of reserpine from davilpepper in the medical technical domain, which comprises the following steps: adding powder of davilpepper root into alcohol; stirring; leaching; filtering to obtain leached liquid; repeating those procedures; decompressing each leached liquid to heat and condense; adopting non-polarity large-hole adsorbing resin to adsorb; washing through water; eluting through alcohol; collecting elution segment by segment; combining reserpine with content over 0.4g/L as total elution; decompressing; heating; condensing; adding water and alkaline; stirring; obtaining solid alkaloid; combining all solid alkaloid to dissolve in the acetone; adding composite solution of chloroform-ligarine; stirring; sedimenting colloid; decompressing supernatant; heating; condensing; obtaining the solid; adding the solid into organic solvent to crystallize; obtaining the product.

The invention discloses a compound traditional Chinese medicine for treating depression. The compound traditional Chinese medicine taking Chinese herbaceous peony, radix bupleurim, turmeric, hyperforin perforatum, purple perilla, rhizoma anemarrhenae and long pepper as raw materials is extracted and separated by 0-75% ethanol and prepared as medically acceptable oral preparations such as troches, capsules (soft or hard capsules) and particles. The drafted major functions of the compound traditional Chinese medicine are soothing liver-qi stagnation and dispersing blood stasis and dredging collateral, and the compound traditional Chinese medicine is used for treating mild-to-moderate depression. The pharmacological researches show that the pharmaceutical composition can remarkably enhance open field activity of chronic stress depression mode mice and increase the consumption of sweet water; antagonizes akinesia and hypothermia of chronic stress depression mode mice induced by reserpine, so that the number of autonomic activities of despair animal mode induced by tail suspension and forced swimming and tail suspension and swimming immobility time are increased. The compound traditional Chinese medicine disclosed by the invention with the functions of soothing liver-qi stagnation is an effective special medicine for treating depression.

A method for treatment of depression and depressive mood disorders. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A, so as to increase synaptic metabolism of serotonin to 5-HIAL. The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day. A caffeine compound may be administered simultaneously so as to compensate for an antihypertensive effect of the reserpine. The caffeine compound may be combined with the reserpine in a transdermal cream.

The invention discloses a method for determining the dissolution rate of five components in compound reserpine tablets through ultra-performance liquid chromatography, and relates to the field of analytic chemistry. The method comprises the steps that gradient elution is performed on a mobile phase composed of a mobile phase A and a mobile phase B; the mobile phase A is a water solution containinghexanesulfonate, wherein the concentration of the hexanesulfonate is 0.05-0.1%, and pH is 2.5-3.0; the mobile phase B is a mixing solution of methyl alcohol and acetonitrile, and the volume ratio ofmethyl alcohol to acetonitrile is (4.5-5.5):1; peaks can be effectively separated out from the five components of vitamin B1, vitamin B6, hydrochlorothiazide, dihydralazine sulfate and promethazine hydrochloride in the compound reserpine tablets, the number of theoretical plates and the separation degree meet the requirements, the separation effect is obvious, and the dissolution rate of five components in compound reserpine tablets can be determined; the method has the advantages of being simple, rapid, high in sensitivity, good in selectivity and the like.

A method for treatment of the symptoms of neurologic dysfunctions, including major depression, an autism spectrum disorder (ASD), and schizophrenia. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A. The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered topically or transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day.

Belonging to the field of pharmacy, the invention relates to a drug resistant Staphylococcus aureus combined drug and application. The drug resistant Staphylococcus aureus combined drug involved in the invention is composed of isoflavone and norfloxacin, wherein the natural compound isoflavone can be separated from plants, is especially high in content in leguminous plants, and has no obvious toxic or side effect. The result of bacteriostatic experiments shows that for norA gene containing fluoroquinolone resistant methicillin-resistant Staphylococcus aureus SA1199B, the isoflavone itself has no bacterial growth inhibiting effect, but after compatibility of the isoflavone and the antibiotic norfloxacin in a ratio of 1:1, the formed combined drug can reduce the minimum bacteriostatic concentration value of norfloxacin by 4 times, and has the same synergistic ability to that of the positive reference substance reserpine. The combined drug provided by the invention can lower the minimum bacteriostatic concentration of norfloxacin, generate an drug-resistant Staphylococcus aureus synergistic effect for norfloxacin, and can be further prepared into drug-resistant Staphylococcus aureus drugs or pharmaceutical preparations for external use.

The invention discloses a compound drug, particularly relating to a compound antihypertensive drug and a preparation method thereof and belonging to the field of medicine technology. The compound antihypertensive drug is prepared by the following bulk drugs according to parts by weight: 2 parts of hydrochlorothiazide, 1.5 parts of dihydralazine sulfate, 2 parts of promethazine hydrochloride, 5 parts of rutin, 2.5 parts of chloroquine phosphate, 30 parts of potassium chloride, 1 part of thiamine hydrochloride, 1 part of pyridoxin hydrochloride, 0.03 part of reserpine, 30 parts of magnesium trisilicate, 2 to 5 parts of starch, 0.1 to 0.8 part of magnesium stearate and 10 to 30 parts of starch slurry. The compound antihypertensive drug generates low fluctuation of blood pressure in the process of reducing blood pressure for hypertension and the compound antihypertensive drug is also characterized by excellent treatment effect, low side effect, high treatment efficiency and long-lasting drug effect.

The invention relates to new application of citron daylily and citron daylily general flavone, and discloses application of citron daylily and citron daylily general flavone to the preparation of medicaments for resisting depression, an particularly discloses application of citron daylily and citron daylily general flavone to the preparation of medicaments for rising serotonin, norepinephrine, dopamine and 5-hydroxyindolacetic acid in cerebral cortex, and discloses application of citron daylily and citron daylily general flavone to the preparation of medicaments for antagonistic reserpine. The application is verified by pharmacological experiments.

The invention belongs to the field of pharmacy, and particularly relates to a compound reserpine medicine composition for treating hypertension and a preparation method of the compound reserpine medicine composition. The compound reserpine medicine composition comprises raw materials in parts by weight as follows: 0.03 parts of reserpine, 1 part of hydralazine hydrochloride, 0.025 parts of cyclopenthiazide, 1.5 parts of hydrochlorothiazide, 2 parts of promethazine hydrochloride, 30 parts of potassium chloride, 5 parts of rutin, 2.5 parts of chloroquine phosphate, 1 part of vitamin B1, 1 part of vitamin B6, 2-10 parts of a stabilizer fumaric acid and other pharmaceutical adjuvants. Experiment results show that the medicine composition takes effect quickly, has long-lasting medicine efficacy, facilitates long-term treatment of a patient and is safe to take; besides, the formula has a high technological stability and is not influenced by environmental temperature and humidity, differences between different bathes of preparations are remarkably reduced, and the stability of samples is improved.

The invention discloses application of a Xinnaoxin capsule in preparation of an antidepressant. According to experimental studies, the Xinnaoxin capsule can substantially reduce dead time during tail suspension and forced swimming of behavioral despair model mice; according to open field experiments, spontaneous activities of the mice are not influenced while dead time is substantially decreased, which prompts that the Xinnaoxin capsule has a certain anti-depression effect. Meanwhile, the Xinnaoxin capsule can substantially inhibit activity of monoamine oxidase and increase the content of a monoamine neurotransmitter in a synaptic cleft, which proves that the Xinnaoxin capsule has the anti-depression effect. Moreover, the Xinnaoxin capsule can substantially antagonize decrease of body temperature of the mice caused by reserpine and apomorphine and increase exogenous toxicity given to NE, which reveals that the capsule has the anti-depression effect. The anti-depression effect of the capsule is realized through improvement of the level of the monoamine neurotransmitter in the synaptic cleft.

The invention discloses application of tetrahydroproberberine compounds to prepare antidepressants. Experiments confirm that tetrahydroproberberine compounds are capable of effectively shortening the swimming motionless time of a depression-model mouse, obviously shortening the tail suspending accumulative motionless time of a depression-model mouse and obviously improving the depression state caused by reserpine of a mouse, and show certain anti-depression effect.

The invention discloses an oral medicament or health care food for treating melancholia with acting mechanism after being made into multiple-target drone receptor with raw materials of ginsenoside (Rg1+Rb1), glycyrrhizic acid and Chinese date cAMP. According to the experiment to prove, the medicament composition of the invention can obviously reduce the small mouse suspension tail dead time and body temperature descend induced by reserpine; obviously improve the rat horizontal and vertical movement increase and rat learning and memory function abatement caused by buibus olfactorius damage; meanwhile can improve saccharose drinking water amount decrease and body weight descend caused by unpredictable long term stress stimulus, can improve the rat horizontal and vertical movement decrease and obvious increase of the NE and 5-HT content in the rat cerebral cortex caused by unpredictable long term stress stimulus. The experiment result proves that the medicament has remarkable anti-melancholia efficacy, comparing to the current medicament Paroxetine for treating the melancholia in prior art.

The invention provides a high-performance liquid chromatography method to determine reserpine quantity in rauvolfia genus. Characteristics: (1) column 18 to carbon alkyl bonded to silica fillers; (2) mobile phase is mixed solventcomposed of acetonitrile, methanol, 0.01% triethylamine, the volume ratio is acetonitrile 45% - 35%, methanol 10% - 25% triethylamine aqueous 45% - 40%, (3) detection wavelength 268 nm, column temperature was 40 deg.C , flow rate 1 ml / min, the sample size of 20 ul. The invention has been system comparative studied, and establish the high-performance liquid chromatography method to determine reserpine quantity in rauvolfia genus for the first time,which is accurate, sensitive, specific, simple and rapid analysis, etc.

The invention discloses a preparation method and medicinal application of CHB which is an effective component of bupleurum Chinese and particularly relates to an application of CHB in preparation of a product for treating depression. The CHB which is the effective component of the bupleurum Chinese has a good effect on treating depression caused by various factors, has a certain protection effect on a U251 cell damaged by corticosterone and has the effects of shortening the tail-suspending immobility time and the swimming immobility time of a mouse and improving the decrease of the body temperature of the mouse due to reserpine. Each dose group is significantly and statistically different from the model group, is dose-dependent and has a good antidepressant function.

The invention provides the application of a saffron crocus pigment composition to the preparation of a medicine for treating or improving depressive disorder, and relates to the field of depressive disorder medicines. Through research findings, the saffron crocus pigment composition can obviously antagonize ptosis of upper eyelid of a mouse caused by reserpine, obviously improve the akinesis condition, obviously reduce the tail suspension immobility time and increase sweet water preference coefficient, so that the saffron crocus pigment composition has a good anti-depression effect, can improve various symptoms of the depressive disorder, serves as an anti-depression medicine and provides a new scheme for research and treatment on the depressive disorder.

The invention relates to applications of a compound cinnamyl-(6'-O-alpha-L-arabopyranose)-O-beta-D-glucopyranoside in pharmaceutical field. The compound can effectively resist blepharoptosis caused by reserpine or akinesia, resist small mouse thrill caused by L-5-HT, resist small mouse tail suspension or acquired desperation depression by a forced swinging method, strengthen L-dopa behavioural effect, and has no exciting or inhibiting effect to nerve centres. The action mechanism thereof may be related to breaking reuptake of NA, DA transmittances so as to increase concentration of the two transmittances in synaptic spaces. The compound has no toxic reactions in acute toxicity experiences on mice so that the compound with experience dosage has relatively high security and good anti-depression effect and can be used to treat depression.